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Abstract
Background: Patient characteristics and blood pressure-related outcomes in randomized clinical trials (RCTs) differ
from clinical practice because of stringent selection criteria. The present study aimed to explore the relationship
between clinical trials and clinical practice. We analyzed data from patients enrolled in the “Treatment with
Azilsartan Compared to ACE-Inhibitors in Anti-Hypertensive Therapy” (EARLY) registry comparing blood pressure (BP)
effects of the angiotensin receptor blocker (ARB) azilsartan medoxomil (AZL-M) with the angiotensin-converting
enzyme (ACE) inhibitor ramipril between patients who met the eligibility criteria of a previous RCT and those who
did not.
Methods: Patients with primary arterial hypertension were consecutively enrolled from primary care offices in
Germany into the EARLY registry in a 7:3 ratio for treatment with AZL-M or an ACE inhibitor, provided that they
met the following criteria at baseline: 1) no antihypertensive treatment prior to inclusion or a non-renin-angiotensin
system (RAS) based monotherapy; 2) initiation of treatment with either AZL-M or an ACE inhibitor alone. Analyses
were performed to evaluate BP effects for patients in the EARLY registry who met the selection criteria of a prior
RCT (RCT+) versus those who did not (RCT-).
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Results: Out of 3,698 patients considered, 1,644 complied with the RCT criteria (RCT+) while 2,054 did not (RCT-).
RCT- patients (55.5 %) displayed a higher risk profile in terms of age and comorbidities, and a wider spectrum of BP
values at baseline, as highlighted by the grades of hypertension and mean BP values. The proportion of patients
who achieved target blood pressure control in the RCT+ group was significantly higher for AZL-M versus ramipril
(64.1 versus 56.1 %; P < 0.01), in accordance with the result of the clinical trial. In the RCT- AZL-M group, the
proportion of patients who met BP targets was lower (58.1 %) than in the RCT+ AZL-M group (64.1 %), whereas
the proportion of patients with target BP values in the RCT- ramipril and the RCT+ ramipril groups was similar
(57.7 versus 56.1 %). Thus, in contrast to results for the RCT+ group, in the RCT- group, the target BP attainment rate for
AZL-M was not significantly superior to that for ramipril. However, the tolerability profile of AZL-M and ramipril was
comparable in both populations. At the 12-month follow-up, death and stroke rates were low (≤0.5 %) and adverse
events did not differ between the AZL-M and ramipril groups, irrespective of RCT eligibility.
Conclusions: These data confirm that the EARLY population comprised a broader spectrum of hypertensive patients
than RCTs, and the differences in patient characteristics were accompanied by disparate rates of blood pressure goal
attainment. Overall, the validity of the RCT was demonstrated and confirmed in clinical practice with a broader range
of patients with various comorbidities.
Keywords: Randomized controlled trial (RCT), Azilsartan-medoxomil, Registry, Hypertension, Clinical practice
Background
There are a number of antihypertensive drugs such as
beta-blockers, angiotensin-converting enzyme (ACE) in-
hibitors, angiotensin receptor blockers (ARBs), calcium
channel blockers, and diuretics being used to treat high
blood pressure [1]. While all drug classes are generally
considered to be effective and safe with differing side ef-
fect profiles based on data from randomized controlled
trials (RCTs), many patients who would not have been
eligible for RCTs have to be treated in clinical practice.
This happens because of the stringent inclusion and ex-
clusion criteria that generally apply for enrollment in an
RCT. For this reason, patients such as those with com-
promised renal function, after myocardial infarction,
those who are particularly young or old (and many
more) are underrepresented in RCTs, but have to be
treated in clinical practice [2].
Azilsartan medoxomil (AZL-M) is a more recently
approved ARB that has been intensively studied in a
number of clinical trials [3–8]. A particular note-
worthy trial compared the antihypertensive efficacy
and safety of AZL-M to ramipril in patients with
grade 1 to 2 hypertension [8]. The primary efficacy
endpoint was the change in clinic trough, seated sys-
tolic blood pressure (BP) from baseline with ambula-
tory BP additionally provided. AZL-M 40 and 80 mg
reduced both clinic systolic BP and mean ambulatory
systolic BP significantly more than ramipril at a dose of
10 mg (clinic SBP −20.6 ± 0.9 with 40 mg and −21.2 ± 0.9
with 80 mg AZL-M versus −12.2 ± 0.9 with ramipril;
P < 0.001 for both doses). Adverse events leading to
discontinuation of treatment were less frequent with
both doses of AZL-M (2.4 % and 3.1 %) compared
with ramipril (4.8 %).
The “Treatment with Azilsartan Compared to ACE-
Inhibitors in Anti-Hypertensive Therapy” (EARLY) regis-
try was conducted in Germany and included patients
who initiated treatment with either AZL-M or an ACE
inhibitor at baseline [9]. In this analysis, patient charac-
teristics, blood pressure control and safety in the EARLY
registry were compared for patients who fulfilled the eli-
gibility criteria for the recent RCT versus patients who
did not.
Methods
The EARLY registry was a prospective, observational,
national, multicenter registry with a 12-month follow-
up. Details of the study protocol have been published
previously [9]. Patients with arterial hypertension who
initiated single-agent treatment with either AZL-M or
an ACE inhibitor in Germany, based on the treating
physicians’ decision, were included in a ratio of seven
(AZL-M) to three (ACE inhibitors). The ratio was
chosen because there is an abundance of data on the
safety and efficacy of ramipril from both RCTs and ob-
servational data. AZL-M, on the other hand, was newly
introduced to the market at the time of this registry.
Thus, we decided to imbalance recruitment in favor of
AZL-M. Patient demographics were recorded at baseline
and at 6- and 12-month follow-up visits. The protocol was
approved by the independent international ethics commit-
tee in Freiburg and the ethics committee of the State
Medical Council of Rheinland-Pfalz, Germany. Written
informed consent was obtained from all patients.
Selection of sites and patients
The registry was conducted in primary care offices in
Germany. To represent the ambulatory treatment of
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hypertension, centers were selected from a database
maintained at the Institut für Herzinfarktforschung,
Ludwigshafen. Adult patients (≥18 years old) with essen-
tial arterial hypertension were consecutively enrolled,
providing that they met the following two criteria: 1) no
anti-hypertensive treatment prior to inclusion or a non-
RAS based antihypertensive monotherapy; 2) monother-
apy using AZL-M or any ACE inhibitor was initiated at
baseline. Exclusion criteria were as follows: 1) treatment
with antihypertensive drugs for an indication other than
hypertension (for example, beta-blockers or diuretics for
heart failure); 2) history of alcohol, drug abuse, or illegal
drug addiction because of an expected lack of compli-
ance with the registry requirements; 3) life expectancy of
less than one year, 4) pregnancy or breast feeding; or
5) participation in other trials or registries. Patients
with contraindications to any of the components of
AZL-M or the ACE inhibitors selected were not per-
mitted to enroll.
Selection criteria
For the present analysis, patients included in the EARLY
registry were divided into two groups according to the
selection criteria used in an RCT by Bönner et al.
(Table 1) that is the only trial available comparing AZL-M
with an ACE inhibitor (ramipril) and thus close to the de-
sign chosen in EARLY [8]. Data were compared for pa-
tients who met the RCT selection criteria relative to those
who did not. Further, patients receiving an ACE inhibitor
other than ramipril were excluded.
Statistics
All summaries are based on the available data. Con-
tinuous variables were summarized with descriptive
Table 1 Selection criteria for the Bönner trial [8] and the corresponding criteria applied to the selection of EARLY patients
Bönner et al. [8] EARLY RCT+ population Proportion of eligible
patients (%)
Inclusion criteria
Age ≥18 years ≥18 years 100.0
SBP 150–180 mmHg 150–180 mmHg 70.0




SBP >180 mmHg >180 mmHg 7.9
DBP >114 mmHg >114 mmHg 2.6
Secondary hypertension Excluded As to SPC
Severe renal disease; eGFR ≤30 ml/1.73 m2 Excluded Renal insufficiency 2.8
Major CV event or intervention <6 month Excluded Stroke excluded 2.7
Sign. cardiac conduction defects Excluded
Aortic valve stenosis Excluded Not recorded
Concomitant antihypertensive treatment or medication
known to affect BP
Excluded Excluded at baseline 32.5
Previous history of cancer not in remission for at least
5 years
Excluded Malignancy excluded 2.6
Type 1 or poorly controlled type 2 diabetes mellitus
(hemoglobin A1c >8.0 %)
Excluded Hemoglobin A1c >8.0 % excluded;
diabetes type not recorded
5.0
Hyperkalemia (serum potassium > upper limit of normal,
5.5 mmol/L)
Excluded Potassium >5.5 mmol/L excluded 0.9
Night shift work Excluded Not recorded
Pregnant or nursing women and woman of childbearing
potential not using approved means of contraception
Excluded Pregnant or nursing women were
excluded
Patients with alcohol or drug abuse Not considered for exclusion Excluded
Treatment
Pre-treatment Not specified Newly diagnosed or non-RAS
monotherapy pretreatment
Treatment AZL-M vs. ramipril AZL-M vs. ramipril; other ACEi
excluded
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statistics (absolute numbers, means, standard devia-
tions (SD), or medians with 25th and 75th percentiles),
as appropriate. Categorical data were recorded as the
number (n) and percentage (%) of patients in each
category. Comparisons between groups were made
with Pearson's chi-squared test for categorical vari-
ables and the Kruskal-Wallis test for continuous mea-
sures. Percentages were determined on the basis of
the number of patients with data available for each
respective parameter (that is, no percentages for miss-
ing values provided).
To evaluate BP differences between groups that dif-
fered at baseline, two multivariate models were used
(Table 3). Model 1 adjusted for SBP/DBP at baseline.
Model 2 adjusted for SBP/DBP at baseline, newly di-
agnosed or established hypertension, age, gender, and
diabetes. Event rates (percentage) at one year are
shown as raw and multivariate-adjusted data with the
following variables considered: SBP/DBP at baseline,
newly diagnosed or established hypertension, age,
gender, and diabetes. Estimated mean differences
were calculated with 95 % CI using a general linear
model.
P-values ≤ 0.05 were considered to indicate statistically
significant differences between groups. All P-values were
calculated using two-sided tests. The statistical analysis
was performed with SAS 9.2 (SAS Institute, Inc., Cary,
NC, USA).
Results
The EARLY registry enrolled 3,849 patients who initi-
ated treatment with either AZL-M or an ACE inhibitor.
Only 151 patients received an ACE inhibitor other than
ramipril, and they were subsequently excluded (Fig. 1).
Of the remaining 3,698 patients, 1,644 complied with
the inclusion and exclusion criteria of the RCT (RCT+)
(Table 1) while 2,054 did not (RCT-). Follow-up was
available for 1,326 patients in the RCT+ group (80.7 %)
and 1,631 patients in the RCT- group (79.4 %). Patient
characteristics for the RCT+ and RCT- groups with or
without a 12-month follow-up are displayed in Additional
file 1: Table S1, which illustrates any potential difference
between those with or without a follow-up.
Patient characteristics
At baseline, the mean age of 3,698 patients receiving ei-
ther AZL-M or ramipril was 59.3 (±13.0) years, 46.6 %
were female, and the mean body weight was 83.4 (±15.6)
kg (Table 2). The mean SBP/DBP was 159.5 (±17.1)/93.5
(±10.5) mmHg, the majority of patients had grade 1
or 2 hypertension (75.6 %), and 6.0 % of patients had
a BP of < 140/90 mmHg. Comorbidities included diabetes
(19.4 %), coronary artery disease (9.6 %), chronic obstruct-
ive pulmonary disease (7.2 %), microalbuminuria (6.6 %),
heart failure (5.7 %), renal disease (3.3 %), peripheral artery
disease (2.9 %), and prior stroke/transient ischemic attack
(2.7 %).
Fig. 1 Patient inclusion and follow-up
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The RCT+ group was younger (P < 0.0001) and had a
higher body weight (P < 0.01). Mean office SBP, DBP,
mean BP, and pulse pressure were all higher in the
RCT+ group (P < 0.0001 for all parameters), and none
of the patients had a BP of < 140/90 mmHg compared
with 10.8 % in the RCT- group (P < 0.0001). With re-
spect to disease severity, the frequency of grade 2
hypertension was higher in the RCT+ group (60.0 %
versus 29.8 %; P < 0.0001), whereas high-normal BP,
and grade 1 and grade 3 hypertension were more fre-
quent in the RCT- group (P < 0.0001 for all). Grade 1
hypertension with end-organ damage was less frequent in
the RCT+ group (53.9 % versus 66.9 %; P < 0.001). The
prevalence of chronic obstructive pulmonary disease was
similar in the RCT+ (6.4 %) and RCT- groups (7.5 %;
P = 0.09), but the prevalence of diabetes was lower in
the RCT+ compared to the RCT- groups (15.3 % ver-
sus 22.6 %; P < 0.0001). All other comorbidities were
less common in the RCT+ group as follows: coronary
artery disease (5.2 % versus 13.2 %; P < 0.0001), prior
stroke/transient ischemic attack (0.0 % versus 4.9 %;
P < 0.0001), known renal disease (1.0 % versus 5.2 %;
P < 0.0001), heart failure (3.0 % versus 7.9 %; P < 0.0001),
microalbuminuria (3.4 % versus 9.1 %; P < 0.0001), and
peripheral artery disease (1.7 % versus 3.8 %; P < 0.001;
Table 2).
BP control with AZL-M versus ramipril by RCT eligibility
For the RCT+ group, raw unadjusted data demonstrated
that reductions in SBP, DBP, and mean pressure were
Table 2 Patient characteristics for the overall group and split by RCT eligibility at baseline with those receiving an ACE inhibitor
other than ramipril excluded (n = 151)
All patients (n = 3,698) RCT(+) (n = 1,644) RCT(−) (n = 2,054) P-value
Age, years 59.3 ± 13.0 57.0 ± 12.8 61.2 ± 12.9 <0.0001
Female, % 46.6 44.0 48.7 <0.01
Body weight, kg 83.4 ± 15.6 83.9 ± 15.1 82.9 ± 16.0 <0.01
BMI, kg/m2 28.4 ± 4.7 28.3 ± 4.4 28.5 ± 5.0 <0.01
Hypertension (HT)
Newly diagnosed HT 37.1 57.2 21.1 <0.0001
Office BP systolic, mmHg 159.5 ± 17.1 162.5 ± 9.5 157.0 ± 21.0 <0.0001
Office BP diastolic, mmHg 93.5 ± 10.5 94.8 ± 8.0 92.5 ± 12.1 <0.0001
Mean BP, mmHg 115.5 ± 10.9 117.4 ± 6.7 114.0 ± 13.2 <0.0001
Pulse pressure, mmHg 65.9 ± 15.2 67.7 ± 10.9 64.4 ± 17.8 <0.0001
BP <140/90 mmHg, % 6.0 0.0 10.8 <0.0001
Hypertension grade
High normal 4.0 0.0 7.2 <0.0001
Grade 1 32.2 25.1 37.9 <0.0001
Any EOD* 62.8 53.9 66.9 <0.001
No EOD* 37.2 46.1 33.1 <0.001
Grade 2 43.4 60.0 29.8 <0.0001
Grade 3 18.5 14.8 21.5 <0.0001
Comorbidity
Diabetes, % 19.4 15.3 22.6 <0.0001
Heart failure, % 5.7 3.0 7.9 <0.0001
CAD, % 9.6 5.2 13.2 <0.0001
Prior stroke/TIA, % 2.7 0.0 4.9 <0.0001
PAD, % 2.9 1.7 3.8 <0.001
COPD, % 7.2 6.4 7.9 0.09
Renal characteristics
Known renal disease (%) 3.3 1.0 5.2 <0.0001
Microalbuminuria, % 6.6 3.4 9.1 <0.0001
Legend: RCT randomized controlled trial, BP blood pressure, EOD end-organ damage, CAD coronary artery disease, TIA transient ischemic attack, PAD peripheral
artery disease, COPD chronic obstructive pulmonary disease. Values are indicated as percentage (%), median (interquartile range), or mean ± standard deviation; *
any EOD is defined as any of diabetes, heart failure, CAD, stroke, PAD, known renal disease, microalbuminuria, or left ventricular hypertrophy
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29.9 mmHg, 14.7 mmHg, and 19.8 mmHg, respectively,
in the AZL-M group compared with 27.1 mmHg,
12.5 mmHg, and 17.4 mmHg in the ramipril group
(P < 0.01, < 0.01, and < 0.001, respectively) (Table 3).
The proportion of patients who attained a target BP
of < 140/90 mmHg was 64.1 % in the AZL-M group
compared with 56.1 % in the ramipril group (P < 0.01).
Using data adjusted for baseline SBP/DBP (model 1), and
baseline SBP/DBP, age, gender, and diabetes (model 2),
AZL-M remained superior to ramipril for SBP, DBP, and
mean BP (P < 0.01), and the percentage of patients with
BP < 140/90 mmHg (P < 0.01).
For the RCT- group, raw unadjusted data indicated
that reductions in SBP, DBP, mean pressure, and pulse
pressure were 22.7 mmHg, 11.6 mmHg, 15.3 mmHg,
and 11.1 mmHg, respectively, in the AZL-M group rela-
tive to 18.9 mmHg, 10.7 mmHg, 13.4 mmHg, and
8.3 mmHg, respectively, in the ramipril group (P < 0.01,
0.07, <0.01, and <0.05, respectively) (Table 3). The pro-
portion of patients who attained target BP levels was
similar in the AZL-M (58.7 %) and the ramipril groups
(57.7 %; P = 0.73). Using models 1 and 2, no significant
differences were observed between the two treatment
groups for any parameter.
Safety profile
After a 12-month follow-up (Table 4), the rate of death
was 4 out of 971 (0.4 %) with AZL-M versus none out of
355 with ramipril in RCT+ patients (P = 0.23). There
were no strokes in either group. Death rates were 0.5 %
with AZL-M versus 0.3 % with ramipril in RCT- patients
(P = 0.61).
The majority of patients in both patient groups,
whether eligible for the RCT or not, had no adverse
events reported during the 1-year follow-up (>90 %)
(Table 4). This percentage was nominally lower in the
RCT+ than in the RCT- group, but with no statistically
significant differences between the AZL-M and ramipril
subgroups. Furthermore, changes in laboratory values as
outlined in Table 4 were clinically negligible, and no sig-
nificant differences were observed for the AZL-M and
ramipril groups, respectively.
Discussion
RCTs act as the principal source of evidence-based data
upon which recommendations in clinical guidelines are
based. Therefore, an appreciation of the differences be-
tween patient demographics and treatment responses in
RCTs compared with clinical practice is of great import-
ance for the successful and widespread implementation
of therapeutic strategies. In the present study, data from
patients in the EARLY registry were grouped and ana-
lyzed according to their eligibility for enrollment in a
previous RCT that compared AZL-M with ramipril [8].
The results 1) demonstrate that the EARLY patient
population not meeting the RCT inclusion criteria
(RCT-) displayed different baseline characteristics and
blood pressure responses compared with those who did
meet the inclusion criteria; 2) demonstrate that in
patients not meeting the RCT inclusion criteria, the dif-
ference in the blood pressure lowering effect between
AZL-M and ramipril was non-significant, at least after
adjustment for baseline variables; and 3) confirmed the
principal result of a strong blood pressure lowering effi-
cacy of AZL-M in the order of 20 mmHg systolic and
11 mmHg diastolic.
Patient selection
The use of selection criteria in RCTs results in a care-
fully selected patient population that is less heteroge-
neous than that seen by primary care physicians. Among
patients in the EARLY registry, 55.5 % were not eligible
for the Bönner RCT. Those patients not eligible for the
RCT were older, had a lower body weight, and lower BP
values. While the majority of patients in both the RCT+
and the RCT- group had grade 1 or 2 hypertension
(85.1 % and 67.7 %, respectively), the RCT- group also
contained patients with high-normal BP, and a greater
proportion of patients with grade 1 hypertension with
end-organ damage, as well as grade 3 hypertension. All
comorbidities except for chronic obstructive pulmonary
disease were more frequent in the RCT- group. In sum-
mary, the RCT- group displayed a higher risk profile in
terms of age and comorbidities, and a wider spectrum of
BP values at baseline, as highlighted by the grades of
hypertension and the mean BP values. These findings
are similar to those of other non-interventional studies;
for example, the “Global Registry of Acute Coronary
Events” (GRACE) demonstrated that RCT-eligible pa-
tients were a lower risk population compared with non-
eligible patients [10]. In the prospective SERVE registry,
which included previously treated patients with inad-
equately controlled hypertension in German clinical
practice, 72 % of patients were not eligible for the corre-
sponding RCT trial COACH [11].
Blood pressure reduction
Data on blood pressure control in the present study in-
dicate that for patients in the RCT+ group, AZL-M was
superior to ramipril for SBP, DBP, and mean pressure, as
well as the proportion of patients who met a target BP
of < 140/90 mmHg. Adjustment for baseline SBP/DBP,
and baseline SBP/DBP, newly diagnosed or established
hypertension, age, gender, and diabetes did not influence
these results. However, for patients in the RCT- group,
while raw data suggested that AZL-M was likewise su-
perior to ramipril for SBP, DBP, pulse pressure, and
mean pressure, differences between the two treatment
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Table 3 Blood pressure reductions: comparison of treatment groups (AZL-M versus ramipril) by RCT eligibility in those with 12-mo. follow-up















Δ Systolic, mmHg 29.9 (29.0–30.9) 27.1 (25.4–28.7) 2.8 (1.1–4.7) <0.01 22.7 (21.5–23.9) 18.9 (16.9–21.0) 3.8 (1.3–6.3) <0.01
Δ Diastolic, mmHg 14.7 (14.1–15.3) 12.5 (11.4–13.6) 2.2 (1.0–3.4) <0.01 11.6 (10.9–12.3) 10.7 (9.4–12.0) 0.9 (−0.6–2.5) 0.07
Δ Mean pressure, mmHg 19.8 (19.2–20.4) 17.4 (16.3–18.5) 2.4 (1.2–3.6) <0.001 15.3 (14.5–16.1) 13.4 (12.1–14.8) 1.9 (0.2–3.5) <0.01
Δ Pulse pressure, mmHg 15.2 (14.4–16.1) 14.5 (13.1–16.0) 0.7 (−1.0–2.4) 0.37 11.1 (10.1–12.1) 8.3 (6.5–10.0) 2.8 (0.7–5.0) <0.05
Δ Heart rate, bpm 3.9 (3.4–4.4) 3.7 (2.9–4.5) 0.7 (−0.7–2.0) 0.45 2.3 (1.6–2.9) 2.2 (1.1–3.4) 0.1 (−1.3–1.3) 0.79
BP <140/90 mmHg, % 64.1 (61.0–67.2) 56.1 (50.7–61.3) n.a. <0.01 58.7 (55.9–61.5) 57.7 (52.4–62.8) n.a. 0.73
Model 1 (adjusted)
Δ Systolic, mmHg 29.7 (28.9–30.4) 27.8 (26.5–29.0) 1.9 (0.4–3.4) <0.05 22.0 (21.3–22.7) 21.6 (20.2–22.9) 0.4 (−1.1–1.9) 0.58
Δ Diastolic, mmHg 14.5 (14.1–15.0) 13.0 (12.2–13.8) 1.5 (0.6–2.5) <0.01 11.4 (10.9–11.8) 11.6 (10.7–12.4) −0.2 (−1.2–0.8) 0.68
Δ Mean pressure, mmHg 19.6 (19.0–20.1) 17.9 (17.0–18.7) 1.7 (0.7–2.6) <0.001 15.0 (14.4–15.4) 15.0 (14.0–15.8) 0.0 (−1.0–1.0) 0.99
Δ Pulse pressure, mmHg 15.1 (14.5–15.8) 14.7 (13.7–15.9) 0.4 (−0.9–1.7) 0.57 10.6 (10.0–11.2) 10.0 (8.8–11.2) 0.6 (−0.7–2.0) 0.35
Δ Heart rate, bpm 3.9 (3.4–4.4) 3.7 (2.9–4.5) 0.2 (−0.7–1.1) 0.65 2.3 (1.9–2.8) 2.0 (1.2–2.8) 0.3 (−0.6–1.3) 0.48
BP <140/90 mmHg, % 64.1 (61.1–67.1) 56.0 (50.8–61.1) n.a. <0.01 58.7 (55.9–61.5) 56.6 (51.4–61.7) n.a. 0.38
Model 2 (adjusted)
Δ Systolic, mmHg 29.7 (28.9–30.5) 27.7 (26.4–28.9) 2.0 (0.6–3.5) <0.01 22.0 (21.3–22.7) 21.4 (20.1–22.7) 0.6 (−0.9–2.1) 0.43
Δ Diastolic, mmHg 14.5 (14.0–15.0) 13.1 (12.3–13.9) 1.4 (0.5–2.4) <0.01 11.1 (10.9–11.8) 11.6 (10.7–12.4) −0.2 (−1.1–0.8) 0.67
Δ Mean pressure, mmHg 19.6 (19.1–20.1) 17.9 (17.1–18.8) 1.6 (0.7–2.6) <0.01 14.9 (14.4–15.4) 14.8 (14.0–15.7) 0.1 (−0.9–1.1) 0.91
Δ Pulse pressure, mmHg 15.2 (14.6–15.9) 14.6 (13.5–15.7) 0.6 (−0.6–1.9) 0.35 10.7 (10.0–11.3) 9.8 (8.7–11.0) 0.8 (−0.5–2.1) 0.22
Δ Heart rate, bpm 3.9 (3.4–4.4) 3.7 (2.9–4.5) 0.2 (−0.7–1.1) 0.66 2.3 (1.9–2.8) 2.0 (1.2–2.8) 0.3 (−0.6–1.3) 0.47
BP <140/90 mmHg, % 64.4 (61.3–67.4) 55.7 (50.4–60.9) n.a. <0.01 59.4 (56.7–62.2) 56.3 (51.0–61.5) n.a. 0.30
Legend: AZL-M azilsartan medoxomil, ACEi angiotensin-converting enzyme inhibitor, rami ramipril, RCT randomized controlled trial, CI confidence interval, BP blood pressure, SBP systolic blood pressure, DBP diastolic
blood pressure, n.a. not applicable. To illustrate the adjusted changes in BP, three pretreatment BP values were chosen to represent the three borders between four quartiles; model 1: adjusted for SBP/DBP at










groups were not maintained after adjustment for con-
founding variables. Accordingly, the difference between
AZL-M and ramipril in the proportion of patients who
achieved a BP target of < 140/90 mmHg was not signifi-
cant when using raw or adjusted data. Interestingly, the
percentage of target BP attainment in the ramipril RCT+
and RCT- groups was consistent, ranging from 56 % to
58 % across all analyses (raw and adjusted data), whereas
for AZL-M, the rate of target BP attainment was 64.1 %
in the RCT+ group and 58.7 % in the RCT- group. This
suggests that the selection criteria used in the previous
RCT of AZL-M versus ramipril may have led to a slight
overestimation of the blood pressure lowering capacity
of AZL-M when compared to ineligible patients or pa-
tients in real-life clinical practice, respectively. The po-
tential reasons for the lack of a difference between both
groups may be caused by 1) the higher age and the lon-
ger duration of hypertension in the RCT- group; 2) the
lower blood pressure at baseline with 11 % being already
controlled; and 3) more patients with diabetes, coronary
artery disease, prior stroke, and renal disease. On the
other hand, the overall conclusion that AZL-M provides
better blood pressure control than ramipril is not invali-
dated by the present analysis, because AZL-M remained
numerically superior to ramipril for patients in the RCT-
group. It is worth noting that the opposite effect was
observed for the RCT COACH: the blood pressure low-
ering effect was underestimated compared with real-life
data from the SERVE registry.
Safety
Safety was assessed based on the recording of adverse
events including death and stroke as well as by record-
ing laboratory values. The overall percentage of any
adverse events was very low with between 5.1 and 9.0 %
reported for the duration of the 12-month observation.
This is in substantial contrast to the RCT [8] where
38.1 % of patients in the AZL-M 40 mg group and
43.7 % of patients in the AZL-M 80 mg group reported
any adverse event and 38.6 % of patients in the ramipril
groups reported any adverse event. This occurred des-
pite the fact that the RCT only had a follow-up of
22 weeks as opposed to 12 months in the current regis-
try. This finding may reinforce the notion that observa-
tional registries, although designed to capture rare
adverse events in real-world clinical practice, may fail to
do so because of the negligence of physicians to actually
report them.
Limitations
Limitations of this analysis are related to the inherent
differences between RCTs and registries reflecting clin-
ical practice. In RCTs, monitoring and follow-up of pa-
tients tend to be more frequent, which may enhance
compliance and persistence to treatment. In the Bönner
et al. [8] RCT of AZL-M versus ramipril, patients were
evaluated at 4-week intervals, whereas, in the EARLY
registry, follow-up was conducted at 6 and 12 months.
Another key difference is the lack of randomization
in patient registries, with physicians being responsible
for the decision to initiate therapy with one drug or
another. This is accompanied by a lack of blinding,
which would prevent a selection bias of patients
based on their characteristics. Finally, though we ad-
justed for SBP/DBP at baseline, newly diagnosed or
established hypertension, age, gender, and diabetes,
we may have failed to adequately consider unknown
bias which can only be alleviated by randomized con-
trolled trials.
Conclusions
The data confirm that the EARLY population comprised
a broader spectrum of patients than the prior RCT
[8], and the differences in patient characteristics were
Table 4 Safety during 1-year follow-up in patients receiving AZL-M or ramipril by RCT eligibility in those with 12-mo. follow-up
RCT eligible RCT not eligible
Adverse events (AEs) at
1 year
RCT(+) AZL-M RCT(+) rami Mean difference
(95 % CI)
P-value RCT(−) AZL-M RCT(−) rami Mean difference
(95 % CI)
P-value
Death, % (95 % CI) 0.4 (0.1–1.1) 0.0 n.a. 0.23 0.5 (0.2–1.0) 0.3 (0.0–1.5) n.a. 0.61
Patients without AE, % 94.0 94.9 n.a. 0.53 92.0 91.0 n.a. 0.51
Patients with any AE, % 6.0 5.1 n.a. 0.53 8.0 9.0 n.a. 0.51
Laboratory values
Δ HbA1c, % 0.02 ± 0.78 0.15 ± 0.72 −0.13 (−0.40–0.14) 0.35 0.01 ± 1.10 0.08 ± 1.06 −0.07 (−0.39–0.25) 0.69
Δ Glucose fasting, mg/dl 5.76 ± 77.68 1.90 ± 19.59 3.85 (−23.65–31.4) 0.91 0.12 ± 21.13 2.81 ± 15.17 −2.69 (−10.70–5.32) 0.37
Δ Creatinine, mg/dl 0.04 ± 0.17 0.01 ± 0.20 0.03 (−0.02–0.08) 0.09 −0.06 ± 1.06 −0.10 ± 1.14 0.04 (−0.22–0.31) 0.90
Δ Potassium, mmol/L 0.05 ± 0.39 0.04 ± 0.53 0.02 (−0.16–0.20) 0.69 0.00 ± 0.51 0.08 ± 0.54 −0.08 (−0.25–0.09) 0.42
Δ GFR, ml/min/1.73 m2 −2.26 ± 10.10 −0.05 ± 11.58 −2.21 (−5.26–0.84) 0.11 −1.45 ± 14.15 −1.08 ± 14.90 −0.37 (−3.86–3.12 ) 0.69
Legend: AZL-M azilsartan medoxomil, rami ramipril, AE adverse event, SAE serious adverse event, GFR glomerular filtration rate, n.a. not applicable
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accompanied by differing percentages of blood pres-
sure goal attainment. The data are important because
they confirm the principal efficacy of AZL-M in clin-
ical practice within a broader range of patients with
various comorbidities.
Additional file
Additional file 1: Table S1. Patient characteristics for the overall group
with those receiving an ACE inhibitor other than ramipril being excluded
(n = 151) and split by RCT eligibility at baseline and availability of the
12-month follow-up. (DOC 53 kb)
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